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functional domains. Mutations within different LRRK2 domains have been considered to be
involved in the development of Parkinson disease by different mechanisms. Our previous study
found three LRRK2 mutationsdp.R767H, p.S885N, and p.R1441Hdin Taiwanese patients with
Parkinson disease.
Methods: We evaluated the functional properties of LRRK2 p.R767H, p.S885N, and
p.R1441H mutations by overexpressing them in human embryonic kidney 293 and neuro-
blastoma SK-N-SH cells. The common p.G2019S mutation in the kinase domain was included
for comparison.
Results: In 293 cells, overexpressed p.R1441Hdbut not p.R767H, p.S885N, or
p.G2019dincreased GTP binding affinity to prolong the active state. Overexpressed
p.R1441H and p.G2019S generated inclusions in 293 cells. In SK-N-SH cells, the a-synuclein
was coexpressed with wild type as well as mutated p.R767H, p.S885N, p.R1441H, and
p.G2019 LRRK2 proteins. Part of the perinuclear inclusions formed by p.R1441H and
p.G2019S were colocalized with a-synuclein. Additionally, p.S885N and p.R1441H muta-
tions caused reduced interaction between LRRK2 and ARHGEF7, a putative guanine nucle-
otide exchange factor for LRRK2, whereas this interaction was well preserved in p.R767H
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lular inclusions, compromises GTP hydrolysis by increasing its affinity for GTP, and reduces
its interaction with ARHGEF7.
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Although the pathogenesis of Parkinson disease (PD) remains
uncertain, the identification of leucine-rich repeat kinase 2
(LRRK2) gene mutations has shed light on understanding the
mechanism and discovering novel therapeutic strategies for
this disease. The LRRK2 gene, encoding a very large 286-kDa
(2527 amino acids) protein,1 is expressed throughout the
basal ganglia, a motor area related to themotor symptoms of
PD, and other nonmotor brain areas such as hippocampus.2
LRRK2 protein (DARDARIN) belongs to the ROCO protein
family, which is characterized by the presence of a Ras
GTPase-like domain termed “Ras of complex protein” (ROC)
immediately followedbyaC-terminalofRocdomain (COR).3,4
In addition toROCandCOR, LRRK2contains several additional
domains, ankyrin-like (ANK) and leucine-rich repeat (LRR)
domains present in the N-terminal and mitogen-activated
protein kinase kinase kinase (MAPKKK) and WD40 domains
present toward the C-terminal end.5 Disturbance of these
enzymatic activities, particularly in kinase and GTPase, is
thought to contribute to the pathogenesis of PD.6
Various mutations located in different domains of LRRK2
result in distinct functional alterations. For example, mu-
tations in the ROC and COR domains (p.K1347A, p.R1441C/
G/H, and p.Y1699C) decrease GTPase activity.7e11
p.G2019S and p.I2020T mutations in the kinase domain
increasing kinase activity,12,13 are required for the full
dominant effects of mutant DARDARIN.14 Hyper-
phosphorylation of GSK3b and MAPK kinase 4 leads to
neuronal degeneration in p.G2019S mutated Drosophila and
transgenic mice, respectively.15,16 It is possible that
different LRRK2 mutations fundamentally affect different
physiological pathways and all lead to PD as a phenotype.
By sequencing the LRRK2 cDNA fragments from 70
Taiwanese early-onset PD patients (age at onset,
50 years) and genotyping 573 Taiwanese patients with PD
and 503 age-matched control individuals, we have identi-
fied one reported (p.R1441H) and two novel missense
(p.R767H and p.S885N) mutations.17 To evaluate the func-
tional roles of these mutations, we overexpressed these
mutated LRRK2 in human embryonic kidney 293 and neu-
roblastoma SK-N-SH cells. Our studies showed that each
mutation demonstrated its unique functional property,
which may contribute to the pathogenesis of PD.Methods
LRRK2, SNCA, and ARHGEF7 cDNA constructs
The wild type LRRK2 cDNA in pCMV6-XL4 was a generous gift
from Dr Eng King Tan of Singapore General Hospital,ang K-H, et al., Functional proper
016), http://dx.doi.org/10.1016/Singapore.18 The LRRK2 translation termination sequence
was removed, and a BamHI restricted site (underlined) was
added using polymerase chain reaction primer 50-
GCGCGGATCCCTCAACAGATG. To generate C-terminal GFP-
tagged LRRK2 protein, the NotIeBamHI fragment contain-
ing full-length LRRK2 cDNA and the BamHIeNotI fragment
containing the EGFP gene (from pEGFP-N3; Clontech,
Mountain View, USA) were inserted into the NotI site of
pcDNA3 vector (Invitrogen, Waltham, USA). To generate the
Myc-His tagged LRRK2 construct, two complementary
primers were annealed to form a double-stranded fragment
containing the Myc-His tag flanked by BamHI and XhoI sites
and used to replace the EGFP sequence. The p.R767H,
p.S885N, p.R1441H, and p.G2019S cDNA plasmids were
generated using Quikchange II site-directed mutagenesis kit
(Stratagene, Santa Clara, USA). The mutated sequence
constructs were confirmed by DNA sequencing.
Polyadenylated RNA (200 ng) isolated from neuroblas-
toma SK-N-SH cells was reverse transcribed using the Su-
perScript III reverse transcriptase (Invitrogen). The sense
and antisense primers for a-synuclein (SNCA, NM_000345)
cDNA amplification were 50-GCGGCCGCCATGGATGTATT-
CATGAAAGG-30 (NotI site underlined) and 50-AGATCTGGC
TTCAGGTTCGTAGTCTTG-30 (BglII site underlined). The
amplified SNCA cDNA was cloned into pGEM-T Easy vector
(Promega, Madison, USA) and sequenced. Then the NotI/
BglII fragment containing SNCA cDNA, BamHI/XhoI frag-
ment containing myc epitope, and polyhistidine tag (from
pcDNA3.1/myc-his; Invitrogen) were used to replace the
LRRK2-EGFP fragment in pcDNA3/LRRK2-EGFP for gener-
ating the Myc-His-tagged SNCA cDNA construct.
To amplify Rho guanine nucleotide exchange factor 7
cDNA (ARHGEF7, NM_145735), the sense and antisense
primers were 50-ATGGATCCATGAATTCCGCCGAGCAAACCGT-
TAC-30 (BamHI site underlined) and 50-GCTTCGAA
GTTCTGGTGAGAGATATATGAGCAACAGC-30 (SfuI site under-
lined), respectively. The amplified ARHGEF7 cDNA was
cloned into pGEM-T Easy vector and sequenced. Subse-
quently, the BamHI/SfuI fragment containingARHGEF7 cDNA
was cloned into the corresponding sites in pcDNA3.1/V5-His/
lacZ to generate theV5-His-taggedARHGEF7 cDNAconstruct.
Cell culture and transient transfection
Human embryonic kidney 293 cells (ATCC No. CRL-1573) and
human neuroblastoma SK-N-SH cells (ATCC No. HTB-11)
were maintained in Dulbecco’s modified Eagle media con-
taining 10% fetal bovine serum in a 37C humidified incu-
bator with a 5% CO2 atmosphere. For transient transfection,
cells were transfected with plasmid DNAs by the lipofection
method (GibcoBRL, Waltham, USA) according to the man-
ufacturer’s recommendations.ties of LRRK2mutations in Taiwanese Parkinson disease, Journal of
j.jfma.2016.04.009
Functional properties of LRRK2 mutations in Taiwanese PD 3
+ MODELGTP binding study
A total of 293 cells were plated into six-well dishes and trans-
fected with the LRRK2-Myc-His constructs (4 mg) as described.
Cells were lysed at 48 hours after transfection in lysis buffer
[1 phosphate buffered saline (PBS), pH 7.4, 1% Triton X-100,
phosphatase inhibitors 10mM NaF, and 1mM Na3VO4) contain-
ing theprotease inhibitor cocktail by rotating at 4C for 1 hour,
and lysates were clarified by centrifugation at 17,500g for
15 minutes at 4C. Supernatants were incubated with g-ami-
nohexyl-GTP-sepharose suspension (Jena Bioscience, Jena,
Germany) by rotating at 4C overnight. The next day, the
pellets were collected by centrifugation, washed three times
with lysis buffer, and subjected to Western blot analysis with
anti-Myc and antiactin antibodies as described below.
Inclusion assay
Briefly, 293 cells were plated into six-well dishes and trans-
fected with the LRRK2-EGFP constructs (4 mg) as described.
The next day, oxaliplatin (5mM; Sigma-Aldrich, St. Louis, USA)
was added for inclusion accumulation through inhibition
of cell division.19 After another day, cells were stained
with Hoechst 33342 (0.1 mg/mL; Sigma-Aldrich), and images
of the cells were automatically obtained using MetaXpress
Image Acquisition and Analysis Software (Molecular Devices,
Sunnyvale, USA), with excitation/emission wavelengths at
482/536 nm (EGFP). Inclusion was determined using Trans-
fluor technology based on GFP intensity.20
Western blot analysis
A total of 293 cells were plated into six-well (6  105/well)
dishes, grown for 20 hours, and transfected with the LRRK2-
EGFP or LRRK2-Myc-His construct (4 mg). After 48 hours, cells
pellets were collected and lysed in hypotonic buffer (20mM
HEPES, pH 7.4, 1mM MgCl2, 10mM KCl, 1mM DTT, 1mM EDTA
pH 8.0) containing the protease inhibitor cocktail (Biovision,
Milpitas, USA). After sonication and sitting on ice for 20 mi-
nutes, the lysateswere centrifuged at 14,000g for 30minutes
at 4C. Protein concentrations were determined with the
protein assay kit (Bio-Rad, Hercules, USA), using albumin as
standards. Total proteins (20 mg) were electrophoresed on
8% sodium dodecyl sulfate-polyacrylamide gel and trans-
ferred onto a nitrocellulose membrane (Schleicher and
Schuell, Dassel, German) by reverse electrophoresis. After
being blocked, the membrane was stained with anti-LRRK2
(1:200 dilution; Abgent, San Diego, USA), anti-Myc (1:1000
dilution; GeneTex, Irvine, USA), anti-GFP (1:500 dilution;
Santa Cruz Biotechnology, Dallas, USA), or anti-actin
(1:10,000 dilution; Millipore, Billerica, USA) antibody. The
immune complexes were detected using horseradish
peroxidase-conjugated goat anti-mouse (Jackson Immu-
noResearch, West Grove, USA) or goat anti-rabbit (Rockland,
Limerick, USA) IgG antibody (1:10,000 dilution) and Immo-
bilon Western Chemiluminescent HRP substrate (Millipore).
Immunocytochemistry and confocal microscopy
SK-N-SH cells were plated into 12-well dishes (on coverslips,
2  105/well), grown for 20 hours, and transfected with thePlease cite this article in press as: Chang K-H, et al., Functional proper
the Formosan Medical Association (2016), http://dx.doi.org/10.1016/LRRK2-EGFP cDNA and SNCA-Myc-His cDNA plasmids (1 mg
each) for 48 hours. Cells were then washed with PBS and
fixed in 4% paraformaldehyde in PBS for 10minutes, followed
by a 20-minute incubation with 0.1% Triton X-100 in PBS to
permeabilize cells and an overnight incubation with 0.5%
bovine serum albumin (BSA) in PBS to block nonspecific
binding. The primary anti-Myc antibody (Santa Cruz
Biotechnology), diluted 1:500 in 1% BSA in Tris-buffered
saline (TBS), was used to stain cells at 4C overnight. After
washing, cells were incubated for 2 hours at room temper-
ature in TRITC-conjugated secondary antibody with 1:500
dilution in TBS containing 1% BSA, and washed in PBS. Nuclei
were detected using 40-6-diamidino-2-phenylindole (DAPI).
After mounting on Vectashield (Vector Laboratories Inc.,
Burlingame, USA), cells were examined for GFP and TRITC
fluorescence using a Leica TCS confocal laser scanning mi-
croscope optimized for simultaneous fluorescent imaging.
Coimmunoprecipitation assay
For LRRK2 and ARHGEF7 coimmunoprecipitation assay,
293 cells were plated into six-well dishes, grown for
20 hours, and transfected with the LRRK2-Myc-His and
ARHGEF7-V5-His cDNA plasmids (3 and 1 mg, respectively).
Vector pcDNA3.1/V5-His was cotransfected with LRRK2-
Myc-His cDNA as a negative control. After 48 hours,
cells were collected and lysed in 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS) lysis
buffer (20mM Tris-basee20mM NaCle1mM EDTAe5mM
EGTAe20mM b-glycerol phosphatee1mM DTTe0.25%
CHAPS) containing protease inhibitor cocktail and phos-
phatase inhibitors (5mM NaFe1mM Na3VO4e20nM Caly-
culin). After sitting on ice for 30 minutes and sonication,
the lysates were centrifuged at 14,000g for 20 minutes at
4C. V5-agarose beads were added and rotated overnight
at 4C. The next day, the collected agarose beads were
washed three times with CHAPS lysis buffer and subjected
to Western blot analysis with anti-Myc, anti-V5 (1:1000
dilution; GeneTex) and antiactin antibodies as described.
Statistical analysis
For each set of values, at least three independent experi-
mentswereperformed.Datawereshownasmeans standard
deviation. Differences between groups were evaluated by
one-way analysis of variance with post hoc Least Significant
Difference (LSD) test where appropriate. All p values were
two-tailed, and p < 0.05 was considered significant.
Results
p.R1441H mutation increased GTP binding activity
Previous reports have shown that LRRK2 mutations within or
close to the ROC domain impair GTPase activity by perturbing
its binding to GTP.9e11 Therefore, the GTP binding activities
of p.R767H, p.S885N, and p.R1441H, located in the ANK
domain, hingedbetween theANKand LRRdomains, and in the
ROC GTPase domain, respectively (Figure 1A), were exam-
ined by overexpressing wild-type and LRRK2 mutations inties of LRRK2mutations in Taiwanese Parkinson disease, Journal of
j.jfma.2016.04.009
Figure 1 LRRK2 domain structure and GTP-binding activities of wild-type and mutated LRRK2. (A) Schematic diagram of LRRK2
multidomains structure. ANK Z ankyrin repeat region; CORZ C terminal of Ras; LRR Z leucine-rich repeat domain;
LRRK2Z leucine-rich repeat kinase 2; MAPKKK Z mitogen-activated protein kinase kinase kinase; ROCZ Ras of complex protein
(GTPase); WD40Z WD40 repeats. The locations of the studied mutations are shown above. The estimated domain boundaries are
indicated by the residue numbers beneath. (B) Myc-tagged wild-type (WT), p.R767H (767), p.S885N (885), p.R1441H (1441), and
p.G2019S (2019) LRRK2 were transfected into 293 cells and GTP-bound LRRK2 level was assessed with anti-Myc antibody. Binding
ratio of LRRK2 variants was compared to the wild-type LRRK2. Mock transfection was used as a negative control. Blots are
representative of three independent experiments. Data were normalized to WT. *p < 0.05 in comparison with wild-type LRRK2.
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domain was included for comparison. As predicted, a signifi-
cantly increased GTP-binding relative to wild-type protein
was seen in LRRK2 p.R1441H mutation (256%, p Z 0.019;
Figure 1B). On the contrary, LRRK2 p.R767H, p.S885N, and
p.G2019S mutations did not affect the GTP-binding activities
(105e140%, p > 0.05).
p.R1441H mutation increased the formation of
cytoplasmic inclusions
Cytoplasmic inclusions were previously observed in 293 cells
transfected with p.R1441C LRRK2.21 To study the inclusion-
forming potential of LRRK2 p.R767H, p.S885N, and
p.R1441H, we overexpressed wild type and mutant LRRK2 in
293 cells. The inclusion-induced p.G2019S mutation22 was
included for comparison. Protein blotting with LRRK2 anti-
body revealed a predicted 300-kDa band representing a full-
length LRRK2-EGFP (Figure 2A). Representative fluorescence
microscopy images of inclusions in wild type and mutant
LRRK2-overexpressed cells are shown in Figure 2B. Whereas
only aminority of cells show apparent cytoplasmic inclusions
in wild type (6.4%) and p.R767H (7.4%), p.S885N (6.4%) mu-
tations, significant inclusions were observed in p.R1441H
(19.1%, pZ 0.009) and p.G2019S (14.8%, PZ 0.028) muta-
tions as compared to the wild type (Figure 2C).
Presence of LRRK2D and a-synucleinD inclusions in
p.R1441H mutation
Intracytoplasmic a-synuclein inclusions are pathological
hallmarks in PD,23 where LRRK2 immunoreactivity was also
shown in a number of a-synuclein pathological inclusions.24Please cite this article in press as: Chang K-H, et al., Functional proper
the Formosan Medical Association (2016), http://dx.doi.org/10.1016/To examine inclusion formation and its association with a-
synuclein, a confocal microscopy examination of LRRK2-
EGFP and a-synuclein co-expressed SK-N-SH cells was per-
formed. Given the large size (13.4 kb) of LRRK2 cDNA con-
structs, approximately 10% transfection efficiency was
achieved as monitored by fused EGFP fluorescence. In
transfected SK-N-SH cells, wild-type LRRK2 was widespread
in cytoplasm and partially in association with a-synuclein
(Figure 3). The distribution of p.R767H, p.S885N, p.R1441H,
and p.G2019S proteins was also mainly in cytoplasm and
partially in association with a-synuclein. Consistent with the
results in 293 cells (Figure 2), an increased number of peri-
nuclear and cytoplasmic LRRK2þ and/or a-synucleinþ in-
clusions were observed by overexpressing p.R1441H and
p.G2019S in SK-N-SH cells (Figure 3).
Reduced interaction between LRRK2 and ARHGEF7
in p.S885N and p.R1441H mutations
ARHGEF7, a putative guanine nucleotide exchange factor of
LRRK2, promotes the exchange of GDP for GTP within the
LRRK2 GTPase domain.25 LRRK2 mutations within the ROC
domain has been shown to disturb the interaction between
LRRK2 and ARHGEF7.25 The interaction of LRRK2-Myc-His
variants with ARHGEF7-V5-His in 293 lysates was examined
by coimmunoprecipitation using V5-agarose beads and
immunoblotting with anti-Myc and anti-V5 antibodies. As
shown in Figure 4, the p.S885N and p.R1441H mutations in
LRRK2 led to a significant binding reduction in mutant
LRRK2 and ARHGEF7 as compared to wild type LRRK2 pro-
tein (52e41% vs. 100%, p Z 0.019e0.022). No significant
difference in LRRK2eARHGEF7 interaction was observed
between p.R767H and p.G2019S mutants as compared to
wild type LRRK2 protein (83e91% vs. 100%, p > 0.05).ties of LRRK2mutations in Taiwanese Parkinson disease, Journal of
j.jfma.2016.04.009
Figure 2 Expression of EGFP-tagged LRRK2 proteins in 293 cells. (A) Western blot analysis of 293 cells transiently expressing wild-
type (WT), p.R767H (767), p.S885N (885), p.R1441H (1441), and p.G2019S (2019) LRRK2 using LRRK2 and b-actin antibodies. (B)
Representative fluorescence microscopy images of LRRK2-EGFP expression after 2 days transfection. (C) Inclusion analysis of
LRRK2-EGFP cells. *p < 0.05 and **p < 0.01, comparison between wild-type and mutated LRRK2.
Figure 3 Confocal microscopy examination of a-synuclein protein in SK-N-SH cells coexpressing wild-type (WT) and p.R767H,
p.S885N, p.R1441H, and p.G2019S mutant LRRK2.
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The results in the present study indicated different func-
tional properties in various LRRK2 mutations. p.R1441HPlease cite this article in press as: Chang K-H, et al., Functional proper
the Formosan Medical Association (2016), http://dx.doi.org/10.1016/increased GTP binding, the formation of cytoplasmic LRRK2
inclusions, but also disturbed the interaction between
LRRK2 and ARHGEF7, whereas p.G2019S increased LRRK2
inclusion formation and p.S885N disturbed the interactionties of LRRK2mutations in Taiwanese Parkinson disease, Journal of
j.jfma.2016.04.009
Figure 4 ARHGEF7 interaction between wild-type and mutated LRRK2. Myc-His-tagged wild-type (WT), p.R767H (767), p.S885N
(885), p.R1441H (1441), and p.G2019S (2019) LRRK2 were cotransfected with V5-His-tagged ARHGEF7 in 293 cells and subjected to
V5 coimmunoprecipitation (IP). Transfection with empty V5 vector was used as a negative control (). Immunoblotting was per-
formed using antibodies against V5 and Myc, respectively. The interaction strength of ARHGEF7 was compared between wild-type
and mutants LRRK2. Blots are representative of three independent experiments. Data were normalized to WT. *p <0.05 in com-
parison with wild-type LRRK2.
6 K.-H. Chang et al.
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LRRK2 inclusions coexpressed with a-synuclein in neuro-
blastoma cells. These data support the notion that
different LRRK2 mutations may affect different pathways.
Similar to p.R1441C/G, p.R1441H also increased GTP
binding affinity.7e9 The binding of LRRK2 to GTP can stim-
ulate kinase activity.26,27 It has been shown that LRRK2
kinase-active mutations (p.R1441C and p.G2019S) form
LRRK2þ aggregations and promote cell death, whereas
kinase-dead mutations block inclusion formation and
strongly delay cell death.14 The accumulation of LRRK2 may
impair proteasome substrate clearance and further induce
the deposition of a-synuclein, leading to the presence of
LRRK2þ and a-synucleinþ aggregations.28 Thus, in our study,
the accumulated p.R1441H or p.G2019S inclusions in
mutant LRRK2-transfected 293 cells may contain a-synu-
clein. Although the relatively low transfection efficiency in
neuronal SK-N-SH cells may be one of the study limitations,
the increased number of perinuclear and cytoplasmic
LRRK2þ and/or a-synucleinþ inclusions in mutant LRRK2-
transfected SK-N-SH cells also supports the notion that
p.R1441H and p.G2019S LRRK2 may inhibit a-synuclein
clearance to enhance the accumulation of a-synuclein and
aggregate formation as previously described.28 Although
not all of them were colocalized, a previous report showed
that coexpression of LRRK2 and a-synuclein did not recruit
a-synuclein into aggregates in cultured cells.29 By contrast,
the enhanced LRRK kinase activity hyperphosphorylates
peroxiredoxin 3 (PRDX3), leading to increased ROS pro-
duction and cell death.30 Thus, LRRK2 kinase inhibitor and
antioxidative compounds may be helpful to ameliorate PD
progression in the patients carrying these gain-of-function
mutations.
ARHGEF7 serves as a guanine nucleotide exchange factor
(GEF) for LRRK2 through mediating the exchange of a GDP
to a GTP binding state.25 Similar to our result, Ha¨big et al25Please cite this article in press as: Chang K-H, et al., Functional proper
the Formosan Medical Association (2016), http://dx.doi.org/10.1016/found that greater binding of GTP to LRRK2 leads to a
reduced binding signal to ARHGEF7 in p.R1441C mutation;
on the contrary, p.G2019S does not change the binding
ability. Coexpression of LRRK2 with ARHGEF7 leads to
reduced LRRK2 binding on GTP-sepharose beads, whereas
coexpression of LRRK2 with a GEF-dead variant of ARHGEF7
does not enhance GTP-bound LRRK2.25 Therefore, the
arginine in the position p.R1441 of LRRK2 in the ROC domain
plays a pivotal role in determining the GTPase activity by
binding to ARHGEF7. Notably, our results showed that the
interaction between LRRK2 and ARHGEF7 is also reduced in
p.S885N mutation. This reduction did not associate with an
increased GTP-binding to LRRK2, suggesting a different
downstream pathway exhibited in p.S885N mutation. The
reduced interaction between p.S885N LRRK2 and ARHGEF7
may link to neuronal degeneration as ARHGEF7 regulates
actin polymerization to affect neurite outgrowth.25
Our results showed that p.R767H did not affect the GTP-
binding activity and its interaction with ARHGEF7, sug-
gesting that p.R767H may be involved in other pathogenic
pathways. The putative PD-associated mutation p.R767H
maps to ANK domain, which is present in a number of
proteins involved in cytoskeleton formation, signal trans-
duction, transcription, and cell cycle regulations.31
Disease-associated mutations are present in ANK domain
of other proteins. Mutations in ANK domain of Notch3 are
associated with cerebral autosomal-dominant arteriopathy
with subcortical infarcts and leukoencephalopathy (CADA-
SIL) by disrupting a proteineprotein interaction.32 Several
mutations located in the ANK domain of cell-cycle inhibitor
p16 leads to inactivation of this tumor suppressor in pa-
tients with familial melanoma.33,34 Located closely to
p.R767H, p.R793M mutation in the ANK domain is also found
in patients with familial PD.35 The presence of these mu-
tations in ANK domain provides clues that ANK domain may
play an indispensable role in the function of LRRK2 andties of LRRK2mutations in Taiwanese Parkinson disease, Journal of
j.jfma.2016.04.009
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to determine if p.R767H mutation is pathogenic and the
underlying mechanism.
In summary, our results demonstrate that each LRRK2
mutation may display its own unique functional character-
istics. It is still uncertain whether these genetic variants
have neurotoxicity to contribute to PD pathogenesis. Our
results need to be validated using neurons or neural tissues
from PD patients carrying mutations. Given that a central
nervous system sample from PD patients is practically
difficult to access, the application of induced pluripotent
cell may be feasible to further studies to explore the
functional roles of these mutations.Acknowledgments
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